Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

@article{As2016DifferentID,
  title={Different infusion durations for preventing platinum-induced hearing loss in children with cancer.},
  author={Jorrit W van As and H. van den Berg and E. C. van Dalen},
  journal={The Cochrane database of systematic reviews},
  year={2016},
  volume={8},
  pages={
          CD010885
        }
}
  • Jorrit W van As, H. van den Berg, E. C. van Dalen
  • Published 2016
  • Medicine
  • The Cochrane database of systematic reviews
  • BACKGROUND Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different platinum infusion durations have been studied. This review is an update of a previously published Cochrane review. OBJECTIVES To assess the effects of different durations… CONTINUE READING
    10 Citations
    Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer
    • 1
    Pharmacological intervention in the field of ototoxicity
    • 8
    • PDF
    Age-corrected hearing loss after chemoradiation in cervical cancer patients
    • 2
    Drug‐induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies
    • 74

    References

    SHOWING 1-10 OF 15 REFERENCES
    Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
    • 361
    • PDF
    Understanding platinum-induced ototoxicity.
    • 128
    Furosemide-induced ototoxicity.
    • 86